| 发明名称 | VEGF analogs | ||
| 摘要 | Modified VEGF proteins that inhibit VEGF-mediated activation or proliferation of endothelial cells are disclosed. The analogs may be used to inhibit VEGF-mediated activation of endothelial cells in angiogenesis-associated diseases such as cancer, inflammatory diseases, eye diseases, and skin disorders. | ||
| 申请公布号 | US9078860(B2) | 申请公布日期 | 2015.07.14 |
| 申请号 | US201414312446 | 申请日期 | 2014.06.23 |
| 申请人 | Trophogen, Inc. | 发明人 | Szkudlinski Mariusz W.;Weintraub Bruce D. |
| 分类号 | A61K38/18;A61K38/16;A61K38/17;C07K14/475;C07K14/52;A61K45/06;A61K38/00 | 主分类号 | A61K38/18 |
| 代理机构 | Morgan Lewis & Bockius LLP | 代理人 | Morgan Lewis & Bockius LLP |
| 主权项 | 1. A human vascular endothelial growth factor A (VEGF-A) receptor antagonist comprising a substitution at an isoleucine residue corresponding to I83 in SEQ ID NO:4 or SEQ ID NO:13, wherein the substitution is a lysine, arginine or histidine, and the substitution results in a decrease in bioactivity as compared to wild-type VEGF. | ||
| 地址 | Rockville MD US | ||